🔗 Share this article WHO Issues Alert Over Acute Lack of Weight-Loss Jabs Under one in 10 patients who could benefit from obesity jabs including Wegovy have access to them, states the global health agency as it issues its initial guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable availability to these injectable treatments. Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our new guidance recognises that obesity is a long-term condition that can be managed with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can assist patients in reducing significant body mass, notes the body. Weight-Loss Drug Supply Crisis Even in the current most favorable case, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, according to the WHO. The guideline calls on governments and firms to expand availability, via measures including voluntary licensing. Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in multiple countries in 2026. The Way Obesity Jabs Function GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and boost satiety so users consume fewer calories. Individuals usually see weight reduction within a few weeks of starting on the once-weekly jabs. Studies indicates users may regain a significant portion after a year of stopping the drug, when their typical hunger return. To be carrying excess weight elevates your chance for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
Under one in 10 patients who could benefit from obesity jabs including Wegovy have access to them, states the global health agency as it issues its initial guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable availability to these injectable treatments. Based on projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken. "Our new guidance recognises that obesity is a long-term condition that can be managed with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and distribution challenges are key obstacles to universal availability to the treatments that can assist patients in reducing significant body mass, notes the body. Weight-Loss Drug Supply Crisis Even in the current most favorable case, the production of GLP-1 therapies could only cover about 100 million people – less than 10% of the global need, according to the WHO. The guideline calls on governments and firms to expand availability, via measures including voluntary licensing. Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is due to expire in multiple countries in 2026. The Way Obesity Jabs Function GLP-1 drugs imitate a biological compound to delay gastric emptying, suppress the appetite and boost satiety so users consume fewer calories. Individuals usually see weight reduction within a few weeks of starting on the once-weekly jabs. Studies indicates users may regain a significant portion after a year of stopping the drug, when their typical hunger return. To be carrying excess weight elevates your chance for developing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies. Obesity concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.